Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government’s Advancing Precision Medicine programme.  The grant-funded project is called “PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool” (the...

Physiomics plc (AIM: PYC), is pleased to announce that, following today’s announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company’s personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT.   The presentation is open to all existing and potential...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.   Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce its audited results for its financial year ended 30 June 2023.   Click here to read in full...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring of a new member of its senior management team.  Effective today, Dr Peter Sargent will be joining the Company as Chief Operating Officer ("COO").   Prior to joining us, Dr Sargent held a senior management role at global consultancy...

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA that it expects to be completed over the next three months.  The project will involve pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage/ repair...

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client, Numab Therapeutics (“Numab”).  The project involves PKPD modelling in support of one of Numab’s clinical programs and follows on from earlier work conducted by Physiomics on the same asset.  The project will...

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”) that it expects to be completed over the next six months.  The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle...

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited.  The Ordinary Shares remain beneficially owned by Dr Millen   Click here to read in full...